Form S-3 | Jotup

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

Retrieved on:

Thursday, February 29, 2024

Attention, Prospectus, Telephone, Milestone, Sale, Paroxysmal supraventricular tachycardia, Form, Nicollet Mall, PSVT, Atrial fibrillation, Security (finance), Form S-3, Offering

MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 16,666,667 of its common shares (the “Shares”) at a public offering price of $1.50 per share and (ii) in lieu of common shares, pre-funded warrants to purchase 3,333,333 common shares at a public offering price of $1.49 per pre-funded warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such pre-funded warrant (“Pre-Funded Warrants” and, together with the Shares the “Securities”).

Key Points:

MONTREAL and CHARLOTTE, N.C., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 16,666,667 of its common shares (the “Shares”) at a public offering price of $1.50 per share and (ii) in lieu of common shares, pre-funded warrants to purchase 3,333,333 common shares at a public offering price of $1.49 per pre-funded warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such pre-funded warrant (“Pre-Funded Warrants” and, together with the Shares the “Securities”).
The proceeds to Milestone from the Offering, before deducting underwriting commissions and offering expenses payable by Milestone, are expected to be approximately $30.0 million.
In addition, Milestone has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 common shares at the public offering price, less underwriting commissions.
The Offering is expected to close on or about March 4, 2024, subject to satisfaction of customary closing conditions.

ClearPoint Neuro Launches Proposed Public Offering of Common Stock

Retrieved on:

Wednesday, February 28, 2024

Prospectus, Spine, Suite, Sale, ATTN:, Form, Security (finance), Form S-3, Brain

SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announced today the commencement of a proposed underwritten public offering of its shares of common stock.

Key Points:

SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, announced today the commencement of a proposed underwritten public offering of its shares of common stock.
The Company also expects to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount of up to 15% of the number of shares sold in the offering.
The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Lake Street Capital Markets, LLC is acting as the sole book-running manager for the proposed offering.

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Retrieved on:

Wednesday, February 28, 2024

Attention, Prospectus, Telephone, Milestone, Sale, Paroxysmal supraventricular tachycardia, Form, Nicollet Mall, PSVT, Atrial fibrillation, Security (finance), Form S-3, Offering

MONTREAL and CHARLOTTE, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares (the “Shares,”), and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares (“Pre-Funded Warrants” and, together with the Shares, the “Securities”).

Key Points:

MONTREAL and CHARLOTTE, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares (the “Shares,”), and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares (“Pre-Funded Warrants” and, together with the Shares, the “Securities”).
In addition, Milestone expects to grant the underwriters a 30-day option to purchase a number of additional common shares equal to 15% of the Securities offered in the Offering.
All Securities to be sold in the Offering will be sold by the Company.
The Offering is subject to market and other conditions and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.

INNOVATE Corp. Announces Rights Offering for Common Stock

Retrieved on:

Monday, February 26, 2024

Prospectus, Rights, Sale, Exercise, Form, The Act, Convertible, Panzer corps, Form S-3, Security (finance)

INNOVATE stockholders who exercise their respective full basic subscription rights will have over-subscription privileges giving such INNOVATE stockholders the option to subscribe for any shares of common stock that remain unsubscribed at the expiration of the rights offering.

Key Points:

INNOVATE stockholders who exercise their respective full basic subscription rights will have over-subscription privileges giving such INNOVATE stockholders the option to subscribe for any shares of common stock that remain unsubscribed at the expiration of the rights offering.
The Company will distribute to each holder of the Company’s common stock as of March 6, 2024 (the “rights offering record date”), one transferable subscription right to purchase shares of the Company’s common stock at a price to be determined prior to commencement of the rights offering.
Holders of the Company’s existing preferred stock and convertible notes that are entitled to participate in dividend distributions to holders of the Company’s common stock will also be entitled to participate in the rights offering.
The Preferred Stock terms will include a liquidation preference junior to the Company’s existing preferred stock and equal to the Company’s common stock (other than a preference of $0.001 per share of Preferred Stock that will be paid to the holders of the Preferred Stock before any payment or distribution is made to the holders of the common stock).

Symbotic Announces Pricing of Primary and Secondary Offering of Class A Common Stock

Retrieved on:

Thursday, February 22, 2024

Goldman Sachs, Prospectus, Telephone, Sale, Form, Attention, Family, Symbotic, Form S-3, Offering, Security (finance)

In the offering, 5,000,000 shares of Class A common stock are being sold by the Company and 5,000,000 shares of Class A common stock are being sold by the Selling Securityholders, each at a public offering price of $40.50 per share.

Key Points:

In the offering, 5,000,000 shares of Class A common stock are being sold by the Company and 5,000,000 shares of Class A common stock are being sold by the Selling Securityholders, each at a public offering price of $40.50 per share.
In addition, Symbotic has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions.
The Selling Securityholders will receive all the net proceeds from the sale of shares of Class A common stock sold by them in the Offering.
The shares of Symbotic’s Class A common stock will be issued pursuant to an effective shelf registration statement on Form S-3.

Symbotic Announces Primary and Secondary Offering of Class A Common Stock

Retrieved on:

Wednesday, February 21, 2024

Goldman Sachs, Prospectus, Telephone, Sale, Form, Attention, Family, Symbotic, Form S-3, Offering, Security (finance)

The Company is offering 5,000,000 shares of its Class A common stock and the Selling Securityholders are offering 5,000,000 shares of Class A common stock.

Key Points:

The Company is offering 5,000,000 shares of its Class A common stock and the Selling Securityholders are offering 5,000,000 shares of Class A common stock.
Symbotic expects to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its Class A common stock at the public offering price, less underwriting discounts and commissions.
The Selling Securityholders will receive all the net proceeds from the sale of shares of Class A common stock sold by them in the Offering.
The shares of Symbotic’s Class A common stock will be issued pursuant to an effective shelf registration statement on Form S-3.

AppLovin Announces Pricing of Secondary Public Offering of Common Stock and Concurrent Share Repurchase

Retrieved on:

Thursday, February 29, 2024

AppLovin will not receive any proceeds from the sale of its Class A common stock by the Selling Stockholder in the offering.

Key Points:

AppLovin will not receive any proceeds from the sale of its Class A common stock by the Selling Stockholder in the offering.
In addition, AppLovin intends to repurchase approximately $570.0 million of the shares of Class A common stock being offered in the offering at the same per share price to be paid by the underwriters to the Selling Stockholder in the offering, inclusive of underwriting discounts and commissions (the “Concurrent Share Repurchase”).
The Concurrent Share Repurchase is conditioned upon the completion of the offering and therefore there can be no assurance that the Concurrent Share Repurchase will be completed.
The offering is not conditioned upon the completion of the Concurrent Share Repurchase.

APi Group Announces Pricing of Upsized Secondary Public Offering of Common Stock

Retrieved on:

Friday, March 1, 2024

APi Group Corporation (NYSE: APG) (“APi” or the “Company”) announced the upsize and pricing of the previously announced underwritten registered public offering of 10,569,106 shares of common stock of the Company commenced by certain funds affiliated with Blackstone Inc. (the “Blackstone Selling Stockholders”) and Viking Global Investors LP (the “Viking Selling Stockholders”), collectively, the “Selling Stockholders,” at a public offering price of $34.25 per share.

Key Points:

APi Group Corporation (NYSE: APG) (“APi” or the “Company”) announced the upsize and pricing of the previously announced underwritten registered public offering of 10,569,106 shares of common stock of the Company commenced by certain funds affiliated with Blackstone Inc. (the “Blackstone Selling Stockholders”) and Viking Global Investors LP (the “Viking Selling Stockholders”), collectively, the “Selling Stockholders,” at a public offering price of $34.25 per share.
The Selling Stockholders received the offered shares upon conversion of then-existing 5.5% Series B Perpetual Convertible Preferred Stock (the “Series B Preferred Shares”).
In connection with the offering, the Selling Stockholders granted the underwriters a 30-day option to purchase up to 1,585,365 additional shares of common stock held by the Selling Stockholders.
APi is not selling any shares of common stock and will not receive any proceeds from the sale of the shares of common stock in the offering.

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Retrieved on:

Tuesday, February 27, 2024

Retail, Restaurant, Bar, Food, Beverage, Prospectus, File, Common stock, 2nd Floor, Sale, Form, Dutch Bros. Coffee, Morgan Stanley, TSG Consumer Partners, Security (finance), Form S-3, BROS

Dutch Bros Inc. (NYSE: BROS; “Dutch Bros” or the “Company”) today announced commencement of a registered underwritten public offering of its Class A common stock, par value $0.00001 per share (the “Common Stock”), by certain selling stockholders associated with TSG Consumer Partners, L.P. (the “Selling Stockholders”).

Key Points:

Dutch Bros Inc. (NYSE: BROS; “Dutch Bros” or the “Company”) today announced commencement of a registered underwritten public offering of its Class A common stock, par value $0.00001 per share (the “Common Stock”), by certain selling stockholders associated with TSG Consumer Partners, L.P. (the “Selling Stockholders”).
The Selling Stockholders intend to offer 8,000,000 shares of Common Stock pursuant to a registration statement on Form S-3 filed with the Securities and Exchange Commission (the “SEC”).
Dutch Bros is not offering any shares of Common Stock in this offering and will not receive any proceeds from the sale of shares of Common Stock by the Selling Stockholders but will bear the costs associated with the sale of such shares, other than any underwriting discounts and commissions.
A shelf registration statement on Form S-3 relating to Dutch Bros’ securities, including the Common Stock, has been filed with the SEC and became effective upon such filing.

Dutch Bros Inc. Announces Pricing of Secondary Public Offering of Class A Common Stock

Retrieved on:

Wednesday, February 28, 2024

Retail, Restaurant, Bar, Food, Beverage, Dutch Bros. Coffee, TSG Consumer Partners, File, Common stock, 2nd Floor, Prospectus, Sale, Morgan Stanley, Form S-3, Form, BROS, Security (finance)

Dutch Bros Inc. (NYSE: BROS; “Dutch Bros” or the “Company”) today announced pricing of the previously announced registered underwritten public offering by certain selling stockholders associated with TSG Consumer Partners, L.P. (the “Selling Stockholders”) of 8,000,000 shares of Dutch Bros’ Class A common stock, par value $0.00001 per share (the “Common Stock”) at a public offering price of $29.05 per share.

Key Points:

Dutch Bros Inc. (NYSE: BROS; “Dutch Bros” or the “Company”) today announced pricing of the previously announced registered underwritten public offering by certain selling stockholders associated with TSG Consumer Partners, L.P. (the “Selling Stockholders”) of 8,000,000 shares of Dutch Bros’ Class A common stock, par value $0.00001 per share (the “Common Stock”) at a public offering price of $29.05 per share.
The offering is expected to close on or about March 1, 2024, subject to the satisfaction of customary closing conditions.
Dutch Bros is not offering any shares of Common Stock in this offering and will not receive any proceeds from the sale of shares of Common Stock by the Selling Stockholders but will bear the costs associated with the sale of such shares, other than any underwriting discounts and commissions.
A shelf registration statement on Form S-3 relating to Dutch Bros’ securities, including the Common Stock, has been filed with the SEC and became effective upon such filing.